Healthcare Equipment and Services laboratory equipment and services

Germany Merck Highlights Tender

📄 Tender ID: 467694027 📅 Published: 24 Nov 2021

📋 Tender Overview

Merck a leading science and technology company today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class andor best-in-class potential at its RD Update Call.At Merck we are working to translate our extensive expertise and deep knowledge in key tumors and neurological and immunological diseases with a goal to change treatment paradigms and improve patient outcomes said Danny Bar-Zohar Global Head of Development for the Healthcare business of Merck. With evobrutinib xevinapant and berzosertib we have the opportunity to be not only first-in-class but potential game-changers in how we treat MS head neck cancer and small cell lung cancer going forward.Advancing Assets with Transformational PotentialEvobrutinib BTK inhibitor A pioneering development program with a new mechanism of action MoA for the treatment of patients with relapsing multiple sclerosis RMS that has the potential to change the standard of care.Oral central nervous system CNS-penetrant covalent Brutons tyrosine kinase inhibitor BTKi in development for RMS.MoA combines potent B-cell inhibition to target acute inflammation associated with relapses with a central effect on microglia that aims to reduce chronic inflammation associated with disease progression.Comprehensive Phase II clinical data support best-in-class potential.Evobrutinib is the first BTKi to have completed enrollment of the Phase III clinical trial program for relapsing multiple sclerosis with data readout expected in Q4 2023.Xevinapant IAP antagonist As a potent oral antagonist of Inhibitor of Apoptosis Proteins IAP and the only IAP antagonist in late-stage development xevinapant builds on our market-leading expertise in squamous cell carcinoma of the head and neck SCCHN aimed at maximizing the chances of a cure in locally advanced disease setting.Ongoing Phase III TrilynX study for previously untreated unresectable locally advanced LA SCCHN in combination with platinum-based chemoradiotherapy.Second global Phase III study to be initiated in the first half of 2022 to evaluate xevinapant in patients with cisplatin-ineligible LA SCCHN.5-year update of OS data from Phase II study anticipated in 2022.First launch expected in 2025.Berzosertib ATR inhibitor The lead candidate in our DNA Damage Response DDR inhibitor portfolio and the first ATR inhibitor with positive randomized clinical trial in any tumor type seeks to exploit the synergistic effect of combining ATR inhibition with topoisomerase I inhibitors Multiple mid-stage clinical trials in small cell lung cancer SCLC build on positive Phase II study results with the goal of establishing a new standard of care in second-line SCLC.Study planned for indication expansion in ovarian cancer and potentially in refractory GI cancers.M1231 MUC1EGFR bi-specific ADC The first bi-specific ADC antibody-drug conjugate from our pipeline that aims to optimize targeting of cancer cells and overcome remaining safety limitations of conventional ADCs.M1231 delivers a cytotoxic payload to tumor cells expressing both MUC1 and EGFR and has a highly controlled drug-antibody ratio which is anticipated to increase tumor specificity selectivity and efficacy.Phase I clinical study to characterize the safety and preliminary activity is well underway and efficacy expansions into late-stage non-small cell lung cancer and esophageal squamous cell carcinoma are expected to begin in 2022.Enpatoran TLR78 inhibitor Oral therapy that aims to overcome limitations of available lupus therapies by providing selective inhibition of lupus-relevant disease drivers which may increase efficacy while preserving immunity against infections.Highly specific potential first-in-class immune modulator blocking the activation of Toll-like receptor TLR7 and TLR8 known to be activated in lupus.Initiation of Phase II studies in systemic lupus erythematosus SLE cutaneous lupus erythematosus CLE in the first half of 2022.Advancing the broader pipeline and portfolioMerck will initiate 11 new studies in 2022 across the early- and late-stage pipeline including a Phase III confirmatory study with tepotinib in EGFRm MET amplification in NSCLC five proof-of-concept studies including trials of M1774 an oral ATR inhibitor being evaluated as both a monotherapy and in combination with PARP inhibitors the JAVELIN Bladder Medley umbrella study in the first-line urothelial carcinoma combining avelumab with novel investigational agents including our anti-TIGIT M6223 and Nektar Therapeutics interleukin-15 IL-15 receptor agonist NKTR-255 in the maintenance setting two first-in-human studies involving M9140 a next-generation ADC based on an internally developed linker-payload technology and M1069 our dual adenosine receptor antagonist.Our rapidly progressing pipeline of in-housediscovered and partnered assets with first-in-class potential demonstrate the deep expertise and collaborative mindset of our RD organization said Joern-Peter Halle Global Head of Research for the Healthcare business of Merck. We expect exciting new entries and substantial advances of our early- and late-stage pipeline in the next few years.

🔍 Key Information

📄
Tender Reference No.
467694027
📅
Publication Date
24 Nov 2021
🌐
Sector
Healthcare Equipment and Services
📝
Notice Type
News
📍
Location
Germany

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 24 Nov 2021
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country Germany
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…